The International Journal of Neuropsychopharmacology
September 1, 2026
N Hartman, D Ivkic, M C Dorczok et al.
Abstract Background Neuropsychiatric manifestations of Long COVID (LC) frequently include post-exertional malaise (Cheng et al., 2025), fatigue, cognitive dysfunction and impairment, sleep disturbances, post-traumatic stress, autonomic dysregulation, pain, inner tension, psychomotor retardation, aberrations in appetite and weight (Badenoch et al., 2022; O'Mahoney et al., 2025), showing...
European Psychiatry
June 23, 2026
Maximilian Preiß, Valentin Popper, Luna Helene Charlotte Faber et al.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Eur Psychiatry
June 16, 2026
A.H. Young, Lucie Bartova, N. Cardoner et al.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Frontiers in Psychiatry
2026
C M Diendorfer, C Bum, A Weidenauer et al.
Schizophrenia (SCZ) is a severe psychiatric condition characterized by positive symptoms such as hallucinations or delusions, as well as negative symptoms such as apathy, anhedonia and avolition. Given their chronic nature and limited response to current treatments, managing negative symptoms is a significant challenge for healthcare providers. Furthermore, many individuals with SCZ suffer from...
European Psychiatry
April 1, 2017
Lucie Bartova, A. Weidenauer, M. Dold et al.
IntroductionTreatment resistant depression (TRD) affecting approximately 10–30% of all depressed patients often remains misdiagnosed and undertreated, leading to a higher risk of relapse and suicide. Electroconvulsive therapy (ECT) and sub-anesthetic ketamine have repeatedly shown to be effective in the TRD population. Administering ketamine as an anesthetic component to augment antidepressant...